Hetero- Hyderabad gets approval for first generic Remdesivir

Date:

Share post:

Dr B Partha Saradhi Reddy, chairman, Hetero Group of Companies, said, “In the light of increasing Covid-19 cases in India, the approval of ‘Covifor’ (Remdesivir) can prove to be a game-changer given its positive clinical outcomes”

Hyderabad-based Hetero has received the manufacturing and marketing approval for the investigational antiviral medicine ‘Remdesivir’ from the Drug Controller General of India (DCGI) for the treatment of Covid-19.

Generic version of Remdesivir, by Hetero, will be marketed under the brand name ‘Covifor’ in India.

Dr B Partha Saradhi Reddy, chairman, Hetero Group of Companies, said, “In the light of increasing Covid-19 cases in India, the approval of ‘Covifor’ (Remdesivir) can prove to be a game-changer given its positive clinical outcomes. Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country. We are prepared for ensuring enough stocks required to cater to the present needs. We will continue to work closely with the government and medical community to make a difference in the fight against Covid-19. This product is made indigenously in line with ‘Make in India’ campaign as envisioned by our  Prime Minister.”

The drug ‘Remdesivir’ has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of Covid-19 in adults and children, hospitalised with severe symptoms of the disease. Covifor (Remdesivir) will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner.

The product is launched under a licensing agreement with Gilead Sciences to expand access to Covid-19 treatment in low and middle-income countries.

ALSO READ: China reports 26 new Covid-19 cases including 22 in Beijing

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Newsletter Signup

Related articles from Tags

Omicron is spreading fast, crossed 200 mark in India: MoHFW reports

Maharashtra and Delhi have reported to reached the highest number of 54 cases of COVID's new variant,...

CBSE announces Special Board Exams for Classes 10 and 12

The Central Board of Secondary Education (CBSE) announced that it will conduct special board exams for classes...

Rise in COVID cases in Chittoor District of Andhra Pradesh

Wile the whole country is just recovering from the shadows of the second wave, the threat of...

Rich People are leaving India for Better Investment says GWM Review

Yes, more and more rich Indians are leaving India for better Investment and opportunities. According to the...

How Dangerous is the Delta Variant?

The fear of the latest Delta Plus variant is coming true. It has spread to about a...

How long can your vaccine protect you from COVID-19

The coronavirus pandemic has hit mankind drastically. Apparently, it has left its scars behind for next 100...

Covid-19 Pandemic has the Positive side too, here is the proof

Covid-19 Pandemic has brought things from better to worse for some. Most of them lost their loved...

COVID-19 Third Wave to Hit India by October: Experts

Around 40 medical experts from around the world participated in a survey by Reuters, the famous media...

COVID Vaccine Gap: AlJazeera Versus NDTV

The government of India extended the COVID vaccine gap between the two doses of the Covishield vaccine...

Kumbh Mela: 1 L Fake COVID-19 Reports issued, Single Phone Number Used For 50 People

In a recent development, The Haridwar district administration ordered an investigation. It alleged that fake COVID-19 test...

Novavax Vaccine: COVID-19 Shot About 90% Effective -Study

American biotechnology company and vaccine maker Novavax said that its vaccine is about 90 per cent effective...

Panic Over Dose Interval of Covishield Vaccine Not Needed -Centre

Media is continuously reporting about the interval between the doses of Covishield vaccine. But, Dr. V.K. Paul...